Chordomas are rare malignant tumors that pose significant challenges in terms of effective treatment options. Surgical resection remains the only established approach that has proven useful in the treatment of chordoma. However, recent evidence has shed light on the role of brachyury, also known as the T-gene and TBXT, as both a diagnostic marker and a potential therapeutic target in chordoma. Considering these developments, this review aims to provide a comprehensive summary of the current knowledge and understanding of brachyury in chordomas.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bbcan.2023.189010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chordoma Spontaneous Regression After COVID-19.
Viruses
December 2024
University Hospital of UFMA, Federal University of Maranhao, São Luís 65080-805, Maranhão, Brazil.
Chordomas are a low-to-intermediate-grade slow-growing subtype of sarcoma, but show propensity to grow and invade locally with recurrence and metastasis in 10-40% of cases. We describe the first case of spontaneous regression of a solid tumor (histologically and immunohistochemically proven chordoma) after COVID-19. A female patient with clival chordoma underwent occipitocervical fixation prior to tumor resection.
View Article and Find Full Text PDFBrachyury co-operates with polycomb protein RYBP to regulate gastrulation and axial elongation .
Front Cell Dev Biol
November 2024
Biological Research Centre, Institute of Genetics, Hungarian Research Network, Szeged, Hungary.
Early embryonic development is a complex process where undifferentiated cells lose their pluripotency and start to gastrulate. During gastrulation, three germ layers form, giving rise to different cell lineages and organs. This process is regulated by transcription factors and epigenetic regulators, including non-canonical polycomb repressive complex 1s (ncPRC1s).
View Article and Find Full Text PDFExtraaxial Poorly Differentiated Chordoma: Clinicopathologic and Molecular Genetic Characterization.
Mod Pathol
November 2024
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota. Electronic address:
Article Synopsis
- In a study of six EAPDC cases, histological features were similar to axial PDC, showing malignant cell characteristics, and genetic analysis revealed common loss of the SMARCB1 gene.
- Follow-up revealed significant clinical challenges, including local recurrences and metastasis within months of surgery, highlighting the aggressive nature and poor prognosis of these rare tumors.
Current understanding of brachyury in chordoma.
Biochim Biophys Acta Rev Cancer
October 2023
Beijing Neurosurgical Institute, Capital Medical University, Beijing, China. Electronic address:
Chordomas are rare malignant tumors that pose significant challenges in terms of effective treatment options. Surgical resection remains the only established approach that has proven useful in the treatment of chordoma. However, recent evidence has shed light on the role of brachyury, also known as the T-gene and TBXT, as both a diagnostic marker and a potential therapeutic target in chordoma.
View Article and Find Full Text PDFRole of immunotherapy in treatment refractory chordomas: review of current evidence.
Front Surg
May 2024
Department of Neurosurgery and Center for Skull Base and Pituitary Surgery, University of Minnesota, Minneapolis, MN, United States.
Introduction: Chordomas are aggressive tumors that are thought to arise from remnants of the embryological notochord. They can arise along the ventromedial aspect of the sacrum, mobile spine, and clivus-with most cases occurring in the sacrum or skull base. Despite surgery and radiation, chordomas often progress and become refractory to further treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!